Last updated: 26 March 2019 at 5:45pm EST

Kalman Fishman Net Worth




The estimated Net Worth of Kalman Fishman is at least $5.9 Million dollars as of 22 March 2019. Kalman Fishman owns over 173 units of Sensus Healthcare Inc stock worth over $5,474,321 and over the last 8 years Kalman sold SRTS stock worth over $425,038.

Kalman Fishman SRTS stock SEC Form 4 insiders trading

Kalman has made over 16 trades of the Sensus Healthcare Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Kalman sold 173 units of SRTS stock worth $1,298 on 22 March 2019.

The largest trade Kalman's ever made was selling 13,019 units of Sensus Healthcare Inc stock on 18 June 2018 worth over $98,033. On average, Kalman trades about 3,958 units every 53 days since 2016. As of 22 March 2019 Kalman still owns at least 931,007 units of Sensus Healthcare Inc stock.

You can see the complete history of Kalman Fishman stock trades at the bottom of the page.



What's Kalman Fishman's mailing address?

Kalman's mailing address filed with the SEC is 851 BROKEN SOUND PARKWAY NW STE 215, , BOCA RATON, FL, 33487.

Insiders trading at Sensus Healthcare Inc

Over the last 8 years, insiders at Sensus Healthcare Inc have traded over $8,288,024 worth of Sensus Healthcare Inc stock and bought 88,000 units worth $292,820 . The most active insiders traders include Joseph C Sardano, Stephen Brad Cohen, and Anthony Benedict Petrelli. On average, Sensus Healthcare Inc executives and independent directors trade stock every 29 days with the average trade being worth of $58,482. The most recent stock trade was executed by John Heinrich on 17 May 2024, trading 20,000 units of SRTS stock currently worth $123,400.



What does Sensus Healthcare Inc do?

sensus healthcare, inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancer and keloids. sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (srt), which is a result of over a decade of dedicated research and development activities. sensus has successfully incorporated the srt therapy into its portfolio of treatment devices: srt-100™ and srt-100 vision™. srt technology effectively and safely treats oncological and non-oncological skin conditions. for more information, visit http://www.sensushealthcare.com.



Complete history of Kalman Fishman stock trades at Sensus Healthcare Inc

Insider
Trans.
Transaction
Total value
Kalman Fishman
Chief Technology Officer
Sale $1,298
22 Mar 2019
Kalman Fishman
Chief Technology Officer
Sale $13,157
10 Sep 2018
Kalman Fishman
Chief Technology Officer
Sale $6,690
28 Aug 2018
Kalman Fishman
Chief Technology Officer
Sale $27,765
8 Aug 2018
Kalman Fishman
Chief Technology Officer
Sale $1,575
2 Aug 2018
Kalman Fishman
Chief Technology Officer
Sale $3,390
26 Jun 2018
Kalman Fishman
Chief Technology Officer
Sale $71,056
21 Jun 2018
Kalman Fishman
Chief Technology Officer
Sale $98,033
18 Jun 2018
Kalman Fishman
Chief Technology Officer
Sale $25,098
27 Oct 2017
Kalman Fishman
Chief Technology Officer
Sale $12,684
13 Sep 2017
Kalman Fishman
Chief Technology Officer
Sale $44,004
7 Sep 2017
Kalman Fishman
Chief Technology Officer
Sale $48,072
5 Sep 2017
Kalman Fishman
Chief Technology Officer
Sale $34,752
25 Aug 2017
Kalman Fishman
Chief Technology Officer
Sale $32,268
23 Aug 2017
Kalman Fishman
Chief Technology Officer
Sale $1,122
1 Dec 2016
Kalman Fishman
Chief Technology Officer
Sale $4,074
29 Nov 2016


Sensus Healthcare Inc executives and stock owners

Sensus Healthcare Inc executives and other stock owners filed with the SEC include: